Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Journal article published in 2019 by
Philip A. Thompson 
,
Jaya Srivastava,
Christine Peterson ,
Paolo Strati,
Jeffrey L. Jorgensen,
Tyler Hether,
Michael J. Keating,
Susan M. O’Brien,
Alessandra Ferrajoli,
Jan A. Burger ,
Zeev Estrov ,
Nitin Jain,
William G. Wierda
,
Jaya Srivastava,
Christine Peterson ,
Paolo Strati,
Jeffrey L. Jorgensen,
Tyler Hether,
Michael J. Keating,
Susan M. O’Brien,
Alessandra Ferrajoli,
Jan A. Burger ,
Zeev Estrov ,
Nitin Jain,
William G. Wierda
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Thompson and colleagues report that detection of minimal residual disease using next-generation sequencing, which is 2 orders of magnitude more sensitive than flow cytometry, is a much better predictor of progression-free survival.